Diffuse large B-cell lymphoma: Reduced CD20 expression is associated with an inferior survival

Blood

Volumn 113, Issue 16, 2009, Pages 3773-3780

  Johnson, Nathalie A ^a   Boyle, Merrill ^a   Bashashati, Ali ^b   Leach, Stephen ^b   Brooks Wilson, Angela ^b   Sehn, Laurie H ^b   Chhanabhai, Mukesh ^a   Brinkman, Ryan R ^b   Connors, Joseph M ^b   Weng, Andrew P ^a,b   Gascoyne, Randy D ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; MONOCLONAL ANTIBODY; TUMOR PROTEIN;

ADULT; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; CYTOPLASM; EXON; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; GENE MUTATION; GENETIC CODE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MUTATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; TUMOR BIOPSY; AGED; BIOSYNTHESIS; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; LARGE CELL LYMPHOMA; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE;

AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD19; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PREDNISONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; VINCRISTINE;

EID: 65549126032     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-09-177469     Document Type: Article

References (50)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumours: Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
2. Clark EA, Shu G, Ledbetter JA. Role of the Bp35 cell surface polypeptide in human B-cell activation. Proc Natl Acad Sci U S A. 1985;82:1766-1770. (Pubitemid 15085258)
3. 1 phase of the cell cycle. J Immunol. 1985;135:3795-3801.
4. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84:2457-2466.
5. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242. (Pubitemid 34438862)
6. Olejniczak SH, Stewart CC, Donohue K, Czuczman MS. A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol Invest. 2006;35:93-114.
7. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833. (Pubitemid 28363048)
8. Mason DY, Comans-Bitter WM, Cordell JL, Verhoeven MA, van Dongen JJ. Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen. Am J Pathol. 1990;136:1215-1222.
9. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31:e15.
10. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 2006;354:2431-2442.
11. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003;100:9991-9996. (Pubitemid 37087056)
12. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275-282.
13. Brooks-Wilson AR, Kaurah P, Suriano G, et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet. 2004;41:508-517. (Pubitemid 38932110)
14. Nickerson DA, Tobe VO, Taylor SL. PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res. 1997;25:2745-2751.
15. Gordon D, Abajian C, Green P. Consed: a graphical tool for sequence finishing. Genome Res. 1998;8:195-202. (Pubitemid 28177231)
16. Serke S, Schwaner I, Yordanova M, Szczepek A, Huhn D. Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: evidence from phenotyping after rituxan therapy and transfectant cell analyses. Cytometry. 2001;46:98-104. (Pubitemid 32423460)
17. Polyak MJ, Ayer LM, Szczepek AJ, Deans JP. A cholesterol-dependent CD20 epitope detected by the FMC7 antibody. Leukemia. 2003;17:1384-1389. (Pubitemid 36857347)
18. Polyak MJ, Deans JP. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes: heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood. 2002;99:3256-3262.
19. Long JC, Aisenberg AC. Richter's syndrome: a terminal complication of chronic lymphocytic leukemia with distinct clinicopathologic features. Am J Clin Pathol. 1975;63:786-795.
20. Yamaguchi M, Seto M, Okamoto M, et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood. 2002;99:815-821. (Pubitemid 34525540)
21. Ennishi D, Takeuchi K, Yokoyama M, et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol. 2008;19:1921-1926.
22. Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M. The epitope recognized by rituximab. Blood. 2006;108:1975-1978.
23. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511. (Pubitemid 30082188)
24. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
25. Lenz G, Wright G, Dave SS, et al. Gene expression signatures predict survival in diffuse large B cell lymphoma following rituximab and CHOP-like chemotherapy. N Engl J Med. 2008;359:2313-2323.
26. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol. 1998;51:364-369. (Pubitemid 28289122)
27. Yang W, Agrawal N, Patel J, et al. Diminished expression of CD19 in B-cell lymphomas. Cytometry B Clin Cytom. 2005;63:28-35.
28. Molica S, Levato D, Dattilo A, Mannella A. Clinicoprognostic relevance of quantitative immunophenotyping in B-cell chronic lymphocytic leukemia with emphasis on the expression of CD20 antigen and surface immunoglobulins. Eur J Haematol. 1998;60:47-52. (Pubitemid 28035759)
29. Rossmann ED, Lundin J, Lenkei R, Mellstedt H, Osterborg A. Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol J. 2001;2:300-306. (Pubitemid 32976373)
30. Lenkei R, Gratama JW, Rothe G, et al. Performance of calibration standards for antigen quantitation with flow cytometry. Cytometry. 1998;33:188-196. (Pubitemid 28447143)
31. Rossmann ED, Lenkei R, Lundin J, Mellstedt H, Osterborg A. Performance of calibration standards for antigen quantitation with flow cytometry in chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2007;72:450-457.
32. Dancescu M, Wu C, Rubio M, Delespesse G, Sarfati M. IL-4 induces conformational change of CD20 antigen via a protein kinase C-independent pathway: antagonistic effect of anti-CD40 monoclonal antibody. J Immunol. 1992;148:2411-2416.
33. Hübl W, Iturraspe J, Braylan RC. FMC7 antigen expression on normal and malignant B-cells can be predicted by expression of CD20. Cytometry. 1998;34:71-74. (Pubitemid 28201475)
34. Delgado J, Matutes E, Morilla AM, et al. Diagnostic significance of CD20 and FMC7 expression in B-cell disorders. Am J Clin Pathol. 2003;120:754-759. (Pubitemid 37339684)
35. Deans JP, Polyak MJ. FMC7 is an epitope of CD20. Blood. 2008;111:2492; author reply 2493-2494.
36. Tam CS, Otero-Palacios J, Abruzzo LV, et al. Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. Br J Haematol. 2008;141:36-40. (Pubitemid 351347535)
37. Chen W, Houldsworth J, Olshen AB, et al. Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas. Blood. 2006;107:2477-2485. (Pubitemid 43345571)
38. Gauld SB, Dal Porto JM, Cambier JC. B cell antigen receptor signaling: roles in cell development and disease. Science. 2002;296:1641-1642. (Pubitemid 34579149)
39. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5:251-262.
40. Feske S. Calcium signalling in lymphocyte activation and disease. Nat Rev Immunol. 2007;7:690-702. (Pubitemid 47327393)
41. Monroe JG. ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat Rev Immunol. 2006;6:283-294.
42. Karnell FG, Brezski RJ, King LB, Silverman MA, Monroe JG. Membrane cholesterol content accounts for developmental differences in surface B cell receptor compartmentalization and signaling. J Biol Chem. 2005;280:25621-25628.
43. Gupta N, DeFranco AL. Lipid rafts and B cell signaling. Semin Cell Dev Biol. 2007;18:616-626.
44. Daniels I, Turzanski J, Haynes AP. A requirement for calcium in the caspase-independent killing of Burkitt lymphoma cell lines by rituximab. Br J Haematol. 2008;142:394-403. (Pubitemid 351962172)
45. Walshe CA, Beers SA, French RR, et al. Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling. J Biol Chem. 2008;283:16971-16984.
46. Meyer zum Buschenfelde C, Feuerstacke Y, Gotze KS, Scholze K, Peschel C. GM1 expression of non-Hodgkin's lymphoma determines susceptibility to rituximab treatment. Cancer Res. 2008;68:5414-5422.
47. O'Connor O, Czuczman MS, LaCasce A, et al. A phase 1 study evaluating the safety, PK & efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies. Ann Oncol. 2008;19:101.
48. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104:1793-1800.
49. Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood. 2008;111:5486-5495.
50. Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 2008;111:1094-1100. (Pubitemid 351213387)